125
0 Kommentare
VERAXA Biotech AG acquires Synimmune GmbH to expand cancer pipeline - Seite 2
125 
0 KommentareDr. Christoph Antz, CEO of VERAXA Biotech AG, stated: «With FLYSYN, we are one step closer to offering better, more effective treatments for those affected by Acute Myeloid Leukemia. »
As we continue to navigate the complexities of AML treatment, VERAXA Biotech AG remains steadfast in its mission to transform the landscape of medical care. For more information about VERAXA Biotech AG and our work in AML treatment, please visit www.veraxa.com.
Lesen Sie auch
Financial calendar
| Annual Report 2023 | 23 April 2024 |
| Annual Shareholders Meeting 2024 | 20 June 2024 |
| Half-Year Report 2024 | 19 September 2024 |
Contact
Information for investors and journalists: Xlife Sciences AG, Dr. Dennis Fink, dennis.fink@xlifesciences.ch
Information related to VERAXA Biotech AG: Dr. Christoph Antz, antz@veraxa.com
Xlife Sciences AG
Talacker 35,
8001 Zurich, Switzerland,
Phone +41 44 385 84 60
info@xlifesciences.ch, www.xlifesciences.ch
Commercial Register Zurich CHE-330.279.788
Stock Exchange: SIX Swiss Exchange
End of Inside Information
| Language: | English |
| Company: | Xlife Sciences AG |
| Talacker 35 | |
| 8001 Zürich | |
| Switzerland | |
| Phone: | +41 44 385 84 60 |
| E-mail: | info@xlifesciences.ch |
| Internet: | www.xlifesciences.ch |
| ISIN: | CH0461929603 |
| Valor: | A2PK6Z |
| Listed: | SIX Swiss Exchange |
| EQS News ID: | 1806049 |
Diskutieren Sie über die enthaltenen Werte
Aktuelle Themen
Weitere Artikel des Autors
URL kopieren
Per E-Mail teilen
Artikel drucken
Artikel zu den Werten
Auch bei Lesern beliebt
